The regulator has received reports that a group of patients treated with Adzynma had neutralizing antibodies against the ...

Moderna is currently in the middle of an aggressive cost-cutting campaign. In September last year, the company announced that ...

Aspen is now also considering the possibility of an initial public offering next year in an effort to bring its cell therapy ...

Eli Lilly has broken free from the Big Pharma pack. Fueled by sky-high expectations for the GLP-1 market, Lilly has achieved ...

The nod brings Bayer face-to-face in the market with Boehringer Ingelheim and AstraZeneca, each of which has its own HER2 ...

A new analysis from Jefferies shows that drugs receiving breakthrough designations sail through the regulatory process more ...

Halda Therapeutics is developing oral assets for prostate and lung cancer. The deal comes after Johnson & Johnson set an ...

Biopharma professionals will probably find decreasing employment opportunities this month and next even as layoffs continue, ...

After revoking Sarepta’s award in July and awarding one to Krystal last month, the FDA’s platform technology designation program appears to be back on track. These six biotechs could be on the ...

Lundbeck had tried to scoop the narcolepsy drug maker out from under Alkeremes with $2.4 billion, but Avadel has elected to ...

The companies have yet to disclose how many programs they plan to collaborate on or what indications they will prioritize.

A week into his tenure as head of the FDA’s Center for Drug Evaluation and Research, experts agree that Rick Pazdur is the ...